In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program

Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales (n = 13,731) and Pseudomonas aeruginosa (n = 4,619) isol...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlowsky, James A., Hackel, Meredith A., Wise, Mark G., Six, David A., Uehara, Tsuyoshi, Daigle, Denis M., Cusick, Susan M., Pevear, Daniel C., Moeck, Greg, Sahm, Daniel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Susceptibility
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872668/
https://www.ncbi.nlm.nih.gov/pubmed/36541767
http://dx.doi.org/10.1128/aac.01281-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872668/
https://www.ncbi.nlm.nih.gov/pubmed/36541767
http://dx.doi.org/10.1128/aac.01281-22

Ejemplares similares